The IGF-I:IGFBP-3 molar ratio, an indicator of bioavailable IGF-I, was consequently lower in patients; 30 % of men with prostate cancer were classified as having high-grade disease (Gleason score ≥7), and 12 % as having locally advanced disease (TNM stages T3-T4). The gene discussed is IGFBP3; the disease is prostate carcinoma.